À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå, Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® ¸®Æ÷Æ® : ÆÄ»ý ¼¼Æ÷º°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2032³â)
Induced Pluripotent Stem Cell Market Share, Size, Trends, Industry Analysis Report, By Derived Cell; By Workflow; By Application; By Region; Segment Forecast, 2024 - 2032
»óǰÄÚµå : 1504923
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 118 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 5,827,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,198,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,569,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ¼¼°è ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 43¾ï 5,556¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ÀÌ Á¶»ç ¸®Æ÷Æ®´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ ÀλçÀÌÆ®¸¦ Á¦½ÃÇϰí, ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ °üÇÑ ºÐ¼®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

³ëÀÎ Àα¸ Áõ°¡, ¸¸¼ºÁúȯ Áõ°¡, ¿¬±¸°³¹ßÀÇ ¹ßÀüÀÌ iPSC ½ÃÀåÀÇ ¼ºÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ÷´Ü ÀǾàǰ °³¹ß ¹× ½ÃÇè¿¡ °ü½ÉÀÌ ÀÖ´Â Àü ¼¼°è Á¦¾àȸ»ç·ÎºÎÅÍ ¸¹Àº ÅõÀÚ¸¦ À¯Ä¡ÇÏ¿© Àüü iPSC ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Áٱ⼼Æ÷ÀÇ Àüü ¿öÅ©Ç÷δ º¹ÀâÇÏÁö¸¸, iPSC »ý»ê°ú °ü·ÃµÈ Áß¿äÇÏ°í º¹ÀâÇÑ ÇÁ·Î¼¼½º¿¡´Â Á¦ÀÛ, ÃʱâÈ­, ´Ù¾çÇÑ ¸ñÀûÀÇ ¼¼Æ÷ À¯ÇüÀ¸·ÎÀÇ ºÐÈ­ µî ´Ù¾çÇÑ Àü¹® Áö½Ä°ú ¸®¼Ò½º°¡ ÇÊ¿äÇÑ Áß¿äÇÑ °úÁ¤ÀÌ Æ÷ÇԵǾî ÀÖÀ¸¸ç, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷¿¡°Ô´Â Ưº°ÇÑ ±âȸÀÔ´Ï´Ù. ÇÊ¿äÇÕ´Ï´Ù. ±×·¯³ª ½ÃÆÇµÇ´Â iPSC À¯·¡ ¼¼Æ÷¸¦ ±¸¸ÅÇϰųª ÇÁ·Î±×·¡¹ÖÀ» ¾Æ¿ô¼Ò½ÌÇÒ ¼ö ÀÖ´Â ¿É¼ÇÀÌ ÀÖÀ¸¹Ç·Î ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷Àº ÀÌ ºÐ¾ß¸¦ °³Ã´ÇÏ°í ¼ºÀå¿¡ ±â¿©ÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ °®°Ô µÉ °ÍÀÔ´Ï´Ù.

½ÃÀå ÁøÀÔÀ» À§ÇÑ ¸î °¡Áö ¼±ÅÃÁö°¡ ÀÖ´Â °¡¿îµ¥, ¸®ÇÁ·Î±×·¡¹Ö ¹× ÀÚü ºÐÈ­¿¡ ÁýÁßÇϰųª, ½ÃÆÇ ÁßÀÎ Á¦Ç° Æ÷Æ®Æú¸®¿À¿¡¼­ iPSC À¯·¡ ¼¼Æ÷ À¯ÇüÀ» ±¸¸ÅÇϰųª, Á¦3°ø±ÞÀÚ¿Í °è¾àÀ» ¸Î¾î ¸ÂÃãÇü ¸ðµ¨À» Á¦ÀÛÇÏ´Â µî ¸î °¡Áö Ãß¼¼°¡ °üÂûµË´Ï´Ù. ÇÏ´Â µî ¸î °¡Áö Ãß¼¼¸¦ °üÂûÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¸¹Àº Áúº´ ¸ðµ¨, Ç¥ÇöÇü ºÐ¼® ¹× µ¶¼º °Ë»ç¿¡ iPSC ±â¹Ý ¸ðµ¨À» »ç¿ëÇÒ ¼ö ÀÖ´Â °¡´É¼º¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿ÀÀǾàǰÀº È£¸£¸ó, ¹é½Å, ´ÜŬ·Ð Ç×ü, Ä¡·á¿ë È¿¼Ò, Ç÷¾× ÀÎÀÚ µî ¹Ì»ý¹°¿¡¼­ À¯·¡ÇÑ ÀǾàǰÀÔ´Ï´Ù. À̵é ÀǾàǰÀº ƯÀ̼ºÀÌ ³ô¾Æ ¸ÂÃãÇü ÀÇ·á µî ÇコÄɾ »õ·Î¿î ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ȯÀÚÀÇ »ý¸®Àû, »ý¹°ÇÐÀû, À¯ÀüÀû ±¸¼º¿¡ µû¶ó ƯÁ¤ »ýü ºÐÀÚ¸¦ »ç¿ëÇÏ¿© ´Ù¾çÇÑ Áúº´°ú Áõ»óÀ» Ä¡·áÇÕ´Ï´Ù. ±âÁ¸ ÀǾàǰÀº Àû¿ë ¹üÀ§°¡ Á¦ÇÑÀûÀÌ°í »ý¸í°øÇÐ ¾÷°è¿¡´Â ±â¾÷ÀÌ ¸¹Áö ¾Ê¾Æ ¼¼Æ÷ ¹è¾ç ±â¼úÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

iPSC ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

2023³â ¼¼°è ½ÃÀåÀº ½É±Ù¼¼Æ÷°¡ Áö¹èÀûÀÎ ºÎ¹®À¸·Î ºÎ»óÇÏ¸ç °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ÀÌ·ç¾ú½À´Ï´Ù. ÀÌ´Â ½ÉÀåÀÇ ¼öÃà°ú ÆßÇÁ ÀÛ¿ëÀ» ´ã´çÇÏ´Â ½ÉÀåÀÇ Æ¯¼ö ±ÙÀ° ¼¼Æ÷ÀÎ ½É±Ù¼¼Æ÷°¡ Ä¡·áÀû ÀÀ¿ë °¡´É¼ºÀ¸·Î ÀÎÇØ Å« ÁÖ¸ñÀ» ¹Þ°í Àֱ⠶§¹®ÀÔ´Ï´Ù.

Àç»ýÀÇ·á »ê¾÷Àº ÇâÈÄ ¼ö³â°£ »ó´çÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àç»ýÀÇ·á´Â ºÎ»óÀ̳ª Áúº´À¸·Î °íÅë¹Þ´Â °³ÀÎÀÇ Á¤»óÀûÀÎ ±â´ÉÀ» ȸº¹Çϱâ À§ÇØ Á¶Á÷°ú Àå±â¸¦ º¹±¸, ´ëü, Àç»ýÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â Ä¡·á ±â¼úÀ» Æ÷ÇÔÇÕ´Ï´Ù.

ºÏ¹Ì´Â »ý¹° ÀÇÇÐ ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ Á¶»ç¿Í ±â¼ú Çõ½ÅÀ¸·Î ¼¼°è ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå : ÆÄ»ý ¼¼Æ÷º°

Á¦6Àå ¼¼°èÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå : ¿ëµµº°

Á¦7Àå ¼¼°èÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå : ¿öÅ©Ç÷ο캰

Á¦8Àå ¼¼°èÀÇ À¯µµ¸¸´ÉÁٱ⼼Æ÷(iPSC) ½ÃÀå : Áö¿ª

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ±â¾÷ °³¿ä

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global Induced Pluripotent Stem Cell (iPSC) market size is expected to reach USD 4,355.56 Million by 2032, according to a new study by Polaris Market Research. The report "iPSC Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Neural Cells, Amniotic Cells, Cardiomyocytes, Others); By Workflow; By Application; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing elderly population, rising cases of chronic diseases, and advancements in research and development are contributing to the increasing growth of the iPSC market. This growth is attracting significant investments from pharmaceutical companies worldwide, who are interested in advanced drug development and testing, and is thereby catering to the overall growth of the iPSC market.

The overall stem cell workflow, although complex, presents a unique opportunity for new entrants in the production of iPSC. Some of the critical and complex processes involved in the production of iPSC include generation, reprogramming, and differentiation into various desired cell types, which require both expertise and resources. However, with the option of commercial iPSC-derived cell purchase or outsourcing programming, new entrants are encouraged to explore this field and contribute to its growth.

With several market entry options available, several trends are observed, such as concentrated efforts on reprogramming and in-house differentiation, purchase of iPSC-derived cell types from off-the-shelf product portfolios, or entering into agreements with third-party purveyors to produce customized models. This trend has spurred a range of possibilities that will feature iPSC-based models for a host of disease models, phenotypic assays, and toxicology testing.

Biopharmaceuticals are drugs that are derived from microbiological sources such as hormones, vaccines, monoclonal antibodies, therapeutic enzymes, blood factors, and so on. These drugs are highly specific and have opened up new avenues in healthcare, such as personalized medicine. This approach involves treating various diseases or conditions using specific biomolecules depending on the patient's physiological, biological, and genetic makeup. As conventional pharmaceuticals have limited applicability and there are few players in the biotechnology industry, the growth of cell culture technology has been fueled.

iPSC Market Report Highlights

In 2023, the global market witnessed significant growth, with cardiomyocytes emerging as the dominant segment. This is because cardiomyocytes, specialized muscle cells in the heart responsible for its contraction and pumping action, have gained significant attention due to their potential for therapeutic applications.

The regenerative medicine industry is projected to experience a substantial growth rate in the upcoming years. Regenerative medicine involves therapeutic techniques that target the repair, replacement, or regeneration of tissues or organs in order to restore normal function in individuals who are suffering from injury or disease.

The North American region dominated the global market, owing to its extensive research and innovation in the field of biomedical science.

The global key market players include Astellas Pharma Inc., Axol Bioscience Ltd., Cynata Therapeutics Limited, Fate Therapeutics, FUJIFILM Holdings Corporation (Cellular Dynamics), Ncardia, REPROCELL Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., ViaCyte, Inc, etc.

Polaris Market Research has segmented the iPSC market report based on derived cell, workflow, application, and region:

iPSC, Derived Cell Outlook (Revenue - USD Million, 2019 - 2032)

iPSC, Workflow Outlook (Revenue - USD Million, 2019 - 2032)

iPSC, Application Outlook (Revenue - USD Million, 2019 - 2032)

iPSC, Regional Outlook (Revenue - USD Million, 2019 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Induced Pluripotent Stem Cell (iPSC) Market Insights

5. Global Induced Pluripotent Stem Cell (iPSC) Market, by Derived Cell

6. Global Induced Pluripotent Stem Cell (iPSC) Market, by Application

7. Global Induced Pluripotent Stem Cell (iPSC) Market, by Workflow

8. Global Induced Pluripotent Stem Cell (iPSC) Market, by Geography

9. Competitive Landscape

10. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â